2 unknown. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Unknown 2 |
| Phase 2 | 1 | Unknown 1 |
Follow CKD: new trials by email Literature Review of CKD trials Research Report on CKD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dapaglifozin to Avoid Acute Kindey Injury (AKI) to Chronic Kidney Disease (CKD) Transition: DAKI-CKD Study Dapagliflozin - AKI - Acute Kidney Injury, Biomarkers | Phase 2 / Phase 3 | Unknown | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 100 | 2023-01-01 | 2024-03-05 |
| The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients Sitagliptin - Covid19, Diabetes Mellitus, Type 2 | Phase 3 | Unknown | University of Milan | 170 | 2021-12-29 | 2021-09-28 |
Acute Kidney Injury (1) · COVID-19 (1) · Diabetes Mellitus, Type 2 (1)
Coronaviridae Infections (1) · Coronavirus Infections (1) · Diabetes Mellitus (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Glucose Metabolism Disorders (1) · Infections (1) · Kidney Diseases (1) · Lung Diseases (1) · Male Urogenital Diseases (1) · Metabolic Diseases (1) · Nidovirales Infections (1) · Nutritional and Metabolic Diseases (1) · Pneumonia (1)
Sitagliptin Phosphate (1) · dapagliflozin (1)
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (1) · University of Milan (1)
Italy (1) · Mexico (1)